Title |
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
|
---|---|
Published in |
Antiviral Research, February 2014
|
DOI | 10.1016/j.antiviral.2014.02.014 |
Pubmed ID | |
Authors |
Lisa Oestereich, Anja Lüdtke, Stephanie Wurr, Toni Rieger, César Muñoz-Fontela, Stephan Günther |
Abstract |
Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is available for use in humans. Here, we evaluated the efficacy of the pyrazinecarboxamide derivative T-705 (favipiravir) against Zaire Ebola virus (EBOV) in vitro and in vivo. T-705 suppressed replication of Zaire EBOV in cell culture by 4log units with an IC90 of 110μM. Mice lacking the type I interferon receptor (IFNAR(-)(/)(-)) were used as in vivo model for Zaire EBOV-induced disease. Initiation of T-705 administration at day 6 post infection induced rapid virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in 100% of the animals. The findings suggest that T-705 is a candidate for treatment of Ebola hemorrhagic fever. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 14% |
Japan | 7 | 10% |
Spain | 2 | 3% |
Mexico | 1 | 1% |
Korea, Democratic People's Republic of | 1 | 1% |
China | 1 | 1% |
Congo, The Democratic Republic of the | 1 | 1% |
Australia | 1 | 1% |
Austria | 1 | 1% |
Other | 6 | 9% |
Unknown | 38 | 55% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 60 | 87% |
Scientists | 4 | 6% |
Science communicators (journalists, bloggers, editors) | 3 | 4% |
Practitioners (doctors, other healthcare professionals) | 2 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | <1% |
Japan | 4 | <1% |
Canada | 3 | <1% |
Indonesia | 2 | <1% |
United Kingdom | 2 | <1% |
France | 1 | <1% |
South Africa | 1 | <1% |
Vietnam | 1 | <1% |
Germany | 1 | <1% |
Other | 4 | <1% |
Unknown | 487 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 95 | 19% |
Researcher | 89 | 17% |
Student > Ph. D. Student | 69 | 14% |
Student > Master | 66 | 13% |
Other | 27 | 5% |
Other | 91 | 18% |
Unknown | 73 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 127 | 25% |
Medicine and Dentistry | 93 | 18% |
Biochemistry, Genetics and Molecular Biology | 48 | 9% |
Chemistry | 38 | 7% |
Immunology and Microbiology | 29 | 6% |
Other | 83 | 16% |
Unknown | 92 | 18% |